MentionFox
Vetmab Biosciences, Inc. filed a Form D with the Securities and Exchange Commission on 2026-09-29.
Sell to companies like these? Paste your website and see 10 with a filed reason to buy this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-29 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Vetmab Biosciences, Inc.
Free to see. No signup.
We'll show it in your MentionFox inbox when Vetmab Biosciences, Inc. raises, hires or launches. No email unless you switch it on.
Watch Vetmab Biosciences, Inc. →Get the full cited report on Vetmab Biosciences, Inc.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Vetmab Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Vetmab Biosciences, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Vetmab Biosciences, Inc. See pricing
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 763 filings in Biotechnology, totalled by week. The dot is this raise, $11.44M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
Developing Life-Changing Therapeutics For Our Pets Monoclonal antibodies (mAbs) for modern veterinary practices Developing Life-Changing Therapeutics For Our Pets Monoclonal... Read More
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Denise Bevers is named as Executive Officer and Director on the Form D that Vetmab Biosciences, Inc. filed with the SEC on 29 September 2026, one of 5 people that filing names.
Richard Chin is named as Executive Officer and Director on the Form D that Vetmab Biosciences, Inc. filed with the SEC on 29 September 2026, one of 5 people that filing names.
Hangjun Zhan is named as Director on the Form D that Vetmab Biosciences, Inc. filed with the SEC on 29 September 2026, one of 5 people that filing names.
Neeraj Agrawal is named as Director on the Form D that Vetmab Biosciences, Inc. filed with the SEC on 29 September 2026, one of 5 people that filing names.
Chrysa Mineo is named as Director on the Form D that Vetmab Biosciences, Inc. filed with the SEC on 29 September 2026, one of 5 people that filing names.
5 people named on the filing — 2 holding an executive role and 3 as directors only.
Named as of the 2026-09-29 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Vetmab Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vetmab Biosciences, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Vetmab Biosciences, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Vetmab Biosciences, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-30 (vetmab.bio).
Each opens in a new tab, filled in for Vetmab Biosciences, Inc.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/vetmab-biosciences-inc-form-d-000002